Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for

首页> > Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial

导出原文传递

翻译打印收藏纠错

第一作者： Rensel, Mary

作者： Rensel, Mary ^[1] ; Zabeti, Aram ^[2] ; Mealy, Maureen A. ^[3] ; Cimbora, Daniel ; She, Dewei ; Drappa, Jorn ; Katz, Eliezer

作者单位： Mellen Ctr Multiple Sclerosis,Cleveland Clin ^[1] Univ Cincinnati ^[2] Horizon Therapeut Plc ^[3]

关键词 Anti-CD19 monoclonal antibody optic neuritis transverse myelitis neuromyelitis optica spectrum disorder

发布时间 2022-08-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial

相似文献

同项目论文

相关期刊

检索历史 清除

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial

相似文献

同项目论文

相关期刊

检索历史清除